At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
Orlistatdrug
Likely dose
Orlistat 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
Albany College of Pharmacy and Health Sciences·interventional·Posted Dec 18, 2009·Updated Apr 4, 2014
In Brief
A Phase 4 clinical trial evaluating Orlistat for Obesity. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The primary goal of the study is to determine if orlistat 60mg (Alli) is effective in helping patients achieve a required 10% weight loss goal prior to bariatric surgery. The medication will be added to the usual standard of care which includes education regarding diet and exercise and monthly meetings with a registered dietician.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsAlbany Medical College
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedDec 2009
Primary CompletionApr 2011
TodayJul 2026
First PostedDec 18, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.5 years ago
Interventions
Orlistatdrug
60mg capsule three times a day for up to 6 months